BioCryst Pharmaceuticals (NASDAQ:BCRX) Coverage Initiated at Wedbush

Wedbush started coverage on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) in a report issued on Tuesday morning, Marketbeat.com reports. The brokerage issued an outperform rating and a $15.00 price target on the biotechnology company’s stock.

BCRX has been the topic of several other research reports. HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday. Barclays raised their price objective on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 5th. Evercore ISI raised their price objective on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a research note on Monday, January 13th. Needham & Company LLC raised their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a “buy” rating in a research note on Monday, January 13th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $15.57.

BioCryst Pharmaceuticals Stock Down 0.1 %

NASDAQ:BCRX opened at $8.28 on Tuesday. BioCryst Pharmaceuticals has a 12 month low of $4.03 and a 12 month high of $9.50. The firm has a market cap of $1.72 billion, a price-to-earnings ratio of -13.57 and a beta of 1.75. The company’s 50 day moving average is $8.05 and its 200-day moving average is $7.85.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06). The firm had revenue of $131.50 million for the quarter, compared to the consensus estimate of $126.64 million. During the same quarter last year, the company posted $0.28 earnings per share. The firm’s revenue for the quarter was up 40.8% on a year-over-year basis. Research analysts predict that BioCryst Pharmaceuticals will post -0.36 EPS for the current fiscal year.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

A number of institutional investors have recently bought and sold shares of BCRX. GF Fund Management CO. LTD. acquired a new stake in BioCryst Pharmaceuticals during the fourth quarter worth $33,000. Venturi Wealth Management LLC acquired a new stake in shares of BioCryst Pharmaceuticals in the 4th quarter valued at $46,000. R Squared Ltd acquired a new stake in shares of BioCryst Pharmaceuticals in the 4th quarter valued at $48,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of BioCryst Pharmaceuticals by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 1,322 shares in the last quarter. Finally, KBC Group NV boosted its stake in shares of BioCryst Pharmaceuticals by 80.1% in the 4th quarter. KBC Group NV now owns 10,198 shares of the biotechnology company’s stock valued at $77,000 after purchasing an additional 4,537 shares in the last quarter. Institutional investors and hedge funds own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.